National Fidaxomicin Prescribing and Spending Trends for C. difficile Infection in Medicare Part D and Medicaid, 2019-2023 (ACG 2026) - Aug 29, 2026 - Abstract #P1294; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "Fidaxomicin, a narrow-spectrum macrocyclic oral antibiotic, is guideline-preferred for CDI due to superior efficacy in reducing recurrence compared with vancomycin. Medicare Part D fidaxomicin spending rose from $44.5 million in 2019 to $127.2 million in 2023 (+186%). Claims increased from 11,904 to 28,662 (+141%) and beneficiaries from 9,154 to 21,562 (+136%). The sharpest increases occurred between 2020 and 2022."
Medicaid • Medicare • Reimbursement • US reimbursement • Infectious Disease
|
|
Utkarsh Dayal MD 1; Dhawani Julka MBBS 2; Aarushi Sudan MD 3; Edwin Saji MD 1; Jason Jacob MBBS 2; Udayakumar Damodaran MD 1; Ann Jacob MBBS 4; Garrick Gu MD 5; Kannu Bansal MD 2
|